> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Strengthen AI-Enabled Clinical Decision Support
- URL: https://www.fdaweb.com/strengthen-ai-enabled-clinical-decision-support/
- Published: 2026-11-19T17:00:00.000Z
- Updated: 2026-11-20T00:10:13.000Z
- Author: David McFarland
- Tags: Devices

Researchers from four academic medical centers say the FDA governance framework for artificial intelligence (AI)-enabled clinical decision support (CDS) could be strengthened by incorporating pragmatic triggers that can help identify scenarios with a heightened risk for clinical decision influence. In a Perspective column in the *Journal of the American Medical Informatics Association*, the researchers [say](https://academic.oup.com/jamia/advance-article-abstract/doi/10.1093/jamia/ocag155/9065616?redirectedFrom=fulltext&ref=fdaweb.com) they reviewed the FDA 1/2026 CDS guidance in the context of the evolving landscape of AI-enabled CDS tools, clinician interaction studies with AI-enabled CDS, and AI governance frameworks.

They report that although the agency’s framework distinguishes non-device CDS from regulated software, AI-enabled CDS may synthesize and transform clinical information in ways that are difficult to verify during routine care, increasing clinician susceptibility to automation bias.

“Pragmatic triggers could help identify scenarios in which nominally reviewable outputs may increase the risk of overreliance on automated recommendations, such as when they are widely adopted, frequently used, deployed in time-sensitive settings, difficult to verify during routine care, or tightly integrated within EHR workflows,” the report concludes. “In these cases, existing governance processes should also assess whether clinicians can meaningfully review and act on AI-enabled CDS outputs, and whether use affects care quality and safety. Serious concerns identified through these processes may warrant escalation to FDA. Oversight calibrated to real-world clinical decision influence is essential to translate independent review from a statutory criterion into a practical safety standard for AI-enabled CDS. The risks of these systems arise not only from what software does but also from how it often subtly shapes clinician decision-making in practice.”